Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Heublein, Sabine [VerfasserIn]   i
 Pfisterer, Jacobus [VerfasserIn]   i
 du Bois, Andreas [VerfasserIn]   i
 Anglesio, Michael [VerfasserIn]   i
 Aminossadati, Behnaz [VerfasserIn]   i
 Bhatti, Irfan A. [VerfasserIn]   i
 Sehouli, Jalid [VerfasserIn]   i
 Wimberger, Pauline [VerfasserIn]   i
 Schochter, Fabienne [VerfasserIn]   i
 Hilpert, Felix [VerfasserIn]   i
 Hillemanns, Peter [VerfasserIn]   i
 Kalder, Matthias [VerfasserIn]   i
 Schroeder, Willibald [VerfasserIn]   i
 Mahner, Sven [VerfasserIn]   i
 Burges, Alexander [VerfasserIn]   i
 Canzler, Ulrich [VerfasserIn]   i
 Gropp-Meier, Martina [VerfasserIn]   i
 Jackisch, Christian [VerfasserIn]   i
 Harter, Philipp [VerfasserIn]   i
 Kommoss, Stefan [VerfasserIn]   i
 Marmé, Frederik [VerfasserIn]   i
Titel:Fibroblast growth factor receptors and ligands in context of bevacizumab response in ovarian carcinoma
Titelzusatz:an exploratory analysis of AGO-OVAR11/ICON-7
Verf.angabe:Sabine Heublein, Jacobus Pfisterer, Andreas du Bois, Michael Anglesio, Behnaz Aminossadati, Irfan Bhatti, Jalid Sehouli, Pauline Wimberger, Fabienne Schochter, Felix Hilpert, Peter Hillemanns, Matthias Kalder, Willibald Schroeder, Sven Mahner, Alexander Burges, Ulrich Canzler, Martina Gropp-Meier, Christian Jackisch, Philipp Harter, Stefan Kommoss, Frederik Marmé
E-Jahr:2024
Jahr:April 2024
Umfang:9 S.
Illustrationen:Illustrationen
Fussnoten:Online verfügbar 27 December 2023, Version des Artikels 15 February 2024 ; Gesehen am 09.10.2024
Titel Quelle:Enthalten in: Laboratory investigation
Ort Quelle:London [u.a.] : Nature Publ. Group, 1996
Jahr Quelle:2024
Band/Heft Quelle:104(2024), 4 vom: Apr., Artikel-ID 100321, Seite 1-9
ISSN Quelle:1530-0307
Abstract:With more novel drugs being approved for the treatment of ovarian carcinoma, the question remains to what extent patients benefit from antiangiogenic treatment with bevacizumab, either in combination with poly-(ADP-ribose) polymerase inhibitors or as single-agent maintenance. As fibroblast growth factor receptors and their ligands (FGFRs/FGFs) are key players in angiogenic signaling and have been linked to resistance to several drugs, we investigated the prognostic or predictive potential of FGFs/FGFRs signaling in the context of bevacizumab treatment within the prospective phase III AGO-OVAR11/ICON-7 study. FGFR1, FGFR2, FGFR3, FGFR4, FGF1, and FGF19 gene expressions were determined in 380 ovarian carcinoma tumor samples collected from German centers in the multicenter phase III AGO-OVAR11 trial/ICON-7 trial. All patients received carboplatin and paclitaxel, administered every 3 weeks for 6 cycles, and were randomized to bevacizumab. Expressions of FGFR1, FGFR2, FGF1, and FGF19 were associated with progression-free survival in both uni- and multivariate (FGFR1: HR, 1.6, P < .001; FGFR2: HR, 1.6, P = .002; FGF1: HR, 2.3, P < .001; and FGF19: HR, 0.7; P = .007) analysis. A signature built by FGFR1, FGFR4, and FGF19 defined a subgroup (n = 62) of patients that derived the greatest bevacizumab-associated improvement of progression-free survival (HR, 0.3; P = .004). In this exploratory analysis of a prospective randomized phase III trial, we provide evidence that the expression of FGFRs/FGFs might have independent prognostic values. An FGFR/FGF-based gene signature identified in our study appears to predict long-term benefit from bevacizumab. This observation is hypothesis-generating and requires validation on independent cohorts.
DOI:doi:10.1016/j.labinv.2023.100321
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.labinv.2023.100321
 Volltext: https://www.sciencedirect.com/science/article/pii/S0023683723002647
 DOI: https://doi.org/10.1016/j.labinv.2023.100321
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:AGO-OVAR 11
 bevacizumab
 fibroblast growth factor
 ICON-7
 ovarian carcinoma
K10plus-PPN:1905206690
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69260755   QR-Code
zum Seitenanfang